Lupin Launches Tadalafil Tablets USP

Pharma major Lupin announced the launch of Tadalafil Tablets USP 20mg, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Tadalafil Tablets USP 20mg is the generic equivalent of Eli Lilly’s Adcirca Tablets 20mg. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Tadalafil Tablets, 20mg (RLD: Adcirca) had annual sales of approximately USD 474.3 million in the US (IQVIA MAT December 2018). – Medical Buyer Bureau